Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.
Department of Nephrology, University Hospital Zurich, Zurich, Switzerland.
Hemodial Int. 2023 Oct;27(4):388-399. doi: 10.1111/hdi.13110. Epub 2023 Aug 6.
The heterogeneous quality of studies on arteriovenous fistulas outcome, with variable clinical settings and large variations in definitions of patency and failure rates, leads to frequent misinterpretations and overestimation of arteriovenous fistula patency. Hence, this study aimed to provide realistic and clinically relevant long-term arteriovenous fistula outcomes.
We retrospectively analyzed all autologous arteriovenous fistulas at our center over a 10-year period (2012-2022). Primary and secondary patency analysis was conducted using the Kaplan-Meier method; multivariate analysis of variance was used to detect outcome predictors. Vascular access-specific endpoints were defined according to the European guidelines on vascular access formation.
Of 312 arteriovenous fistulas, 57.5% (n = 181) were radio-cephalic (RC_AVF), 35.2% (n = 111) brachio-cephalic (BC_AVF), and 6.3% (n = 20) brachio-basilic (BB_AVF). 6, 12, and 24 months follow-up was available in 290 (92.1%), 282 (89.5%), and 259 (82.2%) patients, respectively. Primary patency rates at 6, 12, and 24 months were 39.5%, 34.8%, and 27.2% for RC_AVF, 58.3%, 44.4%, and 27.8% for BC_AVF, and 40.0%, 42.1%, and 22.2% for BB_AVF (p = 0.15). Secondary patency rates at 6, 12, and 24 months were 65.7%, 63.8%, and 59.0% for RC_AVF, 77.7%, 72.0%, and 59.6% for BC_AVF, and 65.0%, 68.4%, and 61.1% for BB_AVF (p = 0.29). Factors associated with lower primary and secondary patency were hemodialysis at time of arteriovenous fistula formation (p = 0.037 and p = 0.024, respectively) and higher Charlson Comorbidity Index (p = 0.036 and p < 0.001, respectively). Previous kidney transplant showed inferior primary patency (p = 0.005); higher age inferior secondary patency (p < 0.001).
Vascular access care remains challenging and salvage interventions are often needed to achieve maturation or maintain patency. Strict adherence to standardized outcome reporting in vascular access surgery paints a more realistic picture of arteriovenous fistula patency and enables reliable intercenter comparison.
由于研究动静脉瘘结果的异质性,临床环境不同,通畅率和失败率的定义也存在较大差异,这导致了对动静脉瘘通畅率的频繁误解和高估。因此,本研究旨在提供现实和临床相关的长期动静脉瘘结果。
我们回顾性分析了我们中心在 10 年内(2012-2022 年)所有的自体动静脉瘘。使用 Kaplan-Meier 法进行主、次通畅分析;使用方差分析多变量检测结果预测因素。根据欧洲血管通路形成指南定义血管通路特异性终点。
312 个动静脉瘘中,57.5%(n=181)为桡动脉-头静脉(RC_AVF),35.2%(n=111)为肱动脉-头静脉(BC_AVF),6.3%(n=20)为肱动脉-贵要静脉(BB_AVF)。290 例(92.1%)、282 例(89.5%)和 259 例(82.2%)患者分别可获得 6、12 和 24 个月的随访。RC_AVF 的 6、12 和 24 个月主通畅率分别为 39.5%、34.8%和 27.2%,BC_AVF 分别为 58.3%、44.4%和 27.8%,BB_AVF 分别为 40.0%、42.1%和 22.2%(p=0.15)。RC_AVF 的 6、12 和 24 个月次通畅率分别为 65.7%、63.8%和 59.0%,BC_AVF 分别为 77.7%、72.0%和 59.6%,BB_AVF 分别为 65.0%、68.4%和 61.1%(p=0.29)。主、次通畅率较低的相关因素包括动静脉瘘形成时进行血液透析(p=0.037 和 p=0.024)和Charlson 合并症指数较高(p=0.036 和 p<0.001)。既往肾移植患者主通畅率较低(p=0.005);年龄较高者次通畅率较低(p<0.001)。
血管通路护理仍然具有挑战性,通常需要进行挽救性干预措施来实现成熟或维持通畅。严格遵循血管通路手术的标准化结果报告可以更真实地描绘动静脉瘘的通畅情况,并实现可靠的中心间比较。